Andrew E.  Place , MD, PhD

Pandey P, Avraham S, Place A, Kumar V, Majumder PK, Cheng K, et al.

Bcl-xL blocks activation of related adhesion focal tyrosine kinase/proline-rich tyrosine kinase 2 and stress-activated protein kinase/c-Jun N-terminal protein kinase in the cellular response to methylmethane sulfonate , 1999/03/20

The Journal of biological chemistry , Page: 274(13):8618-23

PubMed

Ito Y, Pandey P, Place A, Sporn MB, Gribble GW, Honda T, et al.

The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. , 2000/06/14

Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research. , Page: 11(5):261-7.

PubMed

Honda T, Honda Y, Favaloro FG, Jr., Gribble GW, Suh N, Place AE, et al.

A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. , 2002/03/23

Bioorganic & medicinal chemistry letters , Page: 12(7):1027-30

PubMed

Place AE, Suh N, Williams CR, Risingsong R, Honda T, Honda Y, et al.

The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. , 2003/07/12

Clinical cancer research : an official journal of the American Association for Cancer Research. , Page: 9(7):2798-806

PubMed

Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, et al.

The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. , 2005/06/03

Cancer research. , Page: 65(11):4789-98.

Place AE, Jin Huh S, Polyak K.

The microenvironment in breast cancer progression: biology and implications for treatment , 2011/11/15

Breast cancer research : BCR  Issue: 13(6):227

PubMed

Research Overview: Over the last several decades, there have been dramatic improvements in the treatment of the most common types of pediatric cancers. However, despite these successes, relapsed or refractory leukemia carry a dismal prognosis. For example, more children will succumb to relapsed acute lymphoblastic leukemia that any other type of pediatric malignancy. It is paramount that novel agents and treatment strategies are developed for these cancers that improve outcomes while limiting both the acute and long-term toxicities of therapy. In order to achieve these goals, we are developing a robust translational program supported by DF/CHCC’s world-class basic science laboratories, an extensive collection of clinical samples and our extensive experience in clinical trial design and administration. By encouraging collaborations within academia and industry we foster pre-clinical evaluation of the most compelling novel therapies as a mechanism to stream line their introduction into early phase clinical trials.